<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="540">
  <stage>Registered</stage>
  <submitdate>8/03/2005</submitdate>
  <approvaldate>8/03/2005</approvaldate>
  <nctid>NCT00105183</nctid>
  <trial_identification>
    <studytitle>EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection</studytitle>
    <scientifictitle>A Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study of an Anti-human-T-lymphocyte Immune Globulin (EZ-2053) in the Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of Primary Pulmonary Allograft(s)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>EZ-2053-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Obstructive Pulmonary</healthcondition>
    <healthcondition>Idiopathic Pulmonary Fibrosis</healthcondition>
    <healthcondition>Cystic Fibrosis</healthcondition>
    <healthcondition>Bronchiectasis</healthcondition>
    <healthcondition>Pulmonary Vascular Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Connective tissue diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Cystic fibrosis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Placebo
Other interventions - EZ-2053
Other interventions - EZ-2053 5mg/kg

Active Comparator: EZ-2053 - Anti-human-T-lymphocyte Immune Globulin, Rabbit (EZ-2053)

Placebo Comparator: Placebo - USP 0.9% sodium chloride solution

Active Comparator: EZ-2053 5mg/kg - Anti-human-T-Lymphocyte Immune Globulin, Rabbit


Other interventions: Placebo
placebo infusion, single

Other interventions: EZ-2053
single IV infusion, 9 mg/kg

Other interventions: EZ-2053 5mg/kg
single IV infusion, 5mg/kg

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of Participants With the Event Death, Graft Loss, Acute Rejection and/or Loss to Follow-up (Whichever Occurred First)</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Death or Graft Loss Post-transplant</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Acute Rejection</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Infections and Infestations</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Severe Adverse Events</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pulmonary Function Tests, Total Distance Walked 6 Minute Walk Test</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pulmonary Function Test, Forced Vital Capacity</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pulmonary Function Test, Forced Expiratory Volume in 1 Second</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pulmonary Function Test, Forced Expiratory Flow 25-75</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Recipient of a primary single or double pulmonary allograft

          -  Capable of understanding the purposes and risks of the study and has given written
             informed consent, and agrees to comply with the study requirements

          -  Women of childbearing potential must have a negative serum pregnancy test within 4
             days prior to randomization.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Undergoing second or living donor transplant

          -  Prior treatment with T-cell depleting agents within the previous 5 years for the
             purpose of immunosuppression

          -  Prior plasma exchange and/or treatment with IVIg within the past 5 years

          -  Pulmonary infection with pan-resistant Pseudomonas or any Burkholderia species

          -  Known positive blood cultures

          -  Donor lung ischemia time &gt; 8 hours for first lung and &gt; 8 hours for the second lung

          -  Previously received or is receiving a multi-organ transplant

          -  Pregnant women, nursing mothers or women of child-bearing potential who are unwilling
             to use reliable contraception. Effective contraception must be used BEFORE beginning
             study drug therapy, for the duration of the study and for 6 months following
             completion of the study

          -  Active, extra-pulmonary systemic infection requiring the prolonged or chronic use of
             antimicrobial agents or the presence of a chronic active hepatitis B or C

          -  Active liver disease (liver function tests greater than or equal to 2 times the upper
             limit of normal)

          -  Severe anemia (hemoglobin, &lt; 6 g/dL), leukopenia (WBC &lt; 2500/mm3), thrombocytopenia
             (platelet count &lt; 80,000/mm3), polycythemia (Hct &gt; 54% [male], Hct &gt; 49% [female]) or
             clinically significant coagulopathy

          -  Recipient or donor is seropositive for HIV

          -  Previous exposure or known contraindication to administration of the study drug or to
             rabbit proteins

          -  Current malignancy or a history of malignancy (within the previous 5 years), except
             non-metastatic basal cell or squamous cell carcinoma of the skin or carcinoma in-situ
             of the cervix that has been treated successfully

          -  Unstable cardiovascular disease, or a myocardial infarction within the previous 6
             months

          -  Currently participating in another clinical trial with an investigational agent and/or
             is taking or has been taking an investigational agent in the 30 days prior to
             transplant and/or has not recovered from any reversible side effects of prior
             investigational drug

          -  Unlikely to comply with visits schedule in the protocol

          -  Any current history of substance abuse, psychiatric disorder or a condition that, in
             the opinion of the Investigator, may invalidate communication with the Investigator.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>223</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>The Alfred Hospital - Melbourne</hospital>
    <postcode> - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vienna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Edmonton, Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Toronto</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Neovii Biotech</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to assess the efficacy and safety of the study drug, known as
      "ATG Fresenius S," which is sometimes called "EZ-2053," to prevent a lung transplant
      patient's body from rejecting a transplanted lung or lungs.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00105183</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Elbert P Trulock III, MD</name>
      <address>Washington University School of Medicine</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>